Just four months after raising $300 million – and reaching unicorn status in the process – Biofourmis has secured another $20 million in funding, Home Health Care News reports.
In total, the company has amassed a $320 million Series D. Intel Capital, the strategic investment arm of chipmaker Intel Corporation, joined the round.
Biofourmis was originally founded in Singapore, and the company’s U.S. offices are headquartered out of Boston. The company leverages software and data science, along with clinical care teams, to deliver care virtually in the home.
In addition to Intel Capital’s involvement, this funding is especially notable at a time when there’s been a dip in digital health investment. Specifically, there were 329 digital health funding deals in the first half of 2022, compared to 372 deals in the first half of 2021, according to a recent Rock Health report. Read more.
